Suppr超能文献

基于分子对接和分子动力学模拟的中药治疗新型冠状病毒肺炎活性成分虚拟筛选

[Virtual screening of active ingredients of traditional Chinese medicine in treating COVID-19 based on molecular docking and molecular dynamic simulation].

作者信息

Liu Minghao, Faez Iqbal Khan, Xiao Yuqing, Wang Xu, Hu Ziran, Lai Dakun

机构信息

School of Electronic Science and Engineering, University of Electronic Science and Technology of China, Chengdu 610054, P. R. China.

School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu 610054, P. R. China.

出版信息

Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2022 Oct 25;39(5):1005-1014. doi: 10.7507/1001-5515.202205021.

Abstract

We aim to screen out the active components that may have therapeutic effect on coronavirus disease 2019 (COVID-19) from the severe and critical cases' prescriptions in the "Coronavirus Disease 2019 Diagnosis and Treatment Plan (Trial Ninth Edition)" issued by the National Health Commission of the People's Republic of China and explain its mechanism through the interactions with proteins. The ETCM database and SwissADME database were used to screen the active components contained in 25 traditional Chinese medicines in 3 prescriptions, and the PDB database was used to obtain the crystal structures of 4 proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Molecular docking was performed using Autodock Vina and molecular dynamics simulations were performed using GROMACS. Binding energy results showed that 44 active ingredients including xambioona, gancaonin L, cynaroside, and baicalin showed good binding affinity with multiple targets of SARS-CoV-2, while molecular dynamics simulations analysis showed that xambioona bound more tightly to the nucleocapsid protein of SARS-CoV-2 and exerted a potent inhibitory effect. Modern technical methods are used to study the active components of traditional Chinese medicine and show that xambioona is an effective inhibitor of SARS-CoV-2 nucleocapsid protein, which provides a theoretical basis for the development of new anti-SARS-CoV-2 drugs and their treatment methods.

摘要

我们旨在从中华人民共和国国家卫生健康委员会发布的《新型冠状病毒肺炎诊疗方案(试行第九版)》中重症和危重症病例的处方里筛选出可能对2019冠状病毒病(COVID-19)有治疗作用的活性成分,并通过与蛋白质的相互作用来解释其作用机制。利用中药系统药理学数据库(ETCM)和瑞士药物化学数据库(SwissADME)筛选3个处方中25味中药所含的活性成分,利用蛋白质数据银行(PDB)数据库获取严重急性呼吸综合征冠状病毒2(SARS-CoV-2)4种蛋白质的晶体结构。使用Autodock Vina进行分子对接,使用GROMACS进行分子动力学模拟。结合能结果显示,包括纤毛玉凤花皂苷、甘草宁L、木犀草苷和黄芩苷在内的44种活性成分与SARS-CoV-2的多个靶点表现出良好的结合亲和力,而分子动力学模拟分析表明纤毛玉凤花皂苷与SARS-CoV-2的核衣壳蛋白结合更紧密,并发挥了强大的抑制作用。运用现代技术方法研究中药活性成分表明,纤毛玉凤花皂苷是SARS-CoV-2核衣壳蛋白的有效抑制剂,为新型抗SARS-CoV-2药物及其治疗方法的开发提供了理论依据。

相似文献

本文引用的文献

1
Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin.苏拉明抑制 SARS-CoV-2 聚合酶的结构基础。
Nat Struct Mol Biol. 2021 Mar;28(3):319-325. doi: 10.1038/s41594-021-00570-0. Epub 2021 Mar 5.
2
Stabilizing the closed SARS-CoV-2 spike trimer.稳定闭合的 SARS-CoV-2 刺突三聚体。
Nat Commun. 2021 Jan 11;12(1):244. doi: 10.1038/s41467-020-20321-x.
6
Pharmacological treatments of COVID-19.COVID-19 的药物治疗。
Pharmacol Rep. 2020 Dec;72(6):1446-1478. doi: 10.1007/s43440-020-00152-9. Epub 2020 Aug 20.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验